2025 Q3 -tulosraportti
Vain PDF
36 päivää sitten
Tarjoustasot
Määrä
Osto
1 518
Myynti
Määrä
1 020
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,19VWAP
Alin
2,1VaihtoMäärä
0,8 539 340
VWAP
Ylin
2,19Alin
2,1VaihtoMäärä
0,8 539 340
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 8.5.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 10.11. | |
| 2025 Q2 -tulosraportti | 12.8. | |
| 2025 Q1 -tulosraportti | 12.5. | |
| 2024 Q4 -tulosraportti | 17.3. | |
| 2024 Q3 -tulosraportti | 12.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9.7. · MuokattuThere is no answer before the stock market opens or the days go by. But from after/before trading, the big sums and green numbers are going since yesterday's close - at the time of writing over $5. Can the FDA meeting in the coming weeks be a trigger in itself and create fomo? I have read posts on the US forum when it was last at about $2.5, which mentioned 5X 10X at the time (no answer). Clearly, just a small market share can mean several 100 million a year in revenue. Regarding the short in the stock, it is large and explosive. The company has probably caught them on their heels: ProKidney (PROK) has a short interest of 16.80 million shares, representing 17.84% of the float (the number of shares available for trading by the public). This marks a 1.69% increase in short interest from the previous month. The short interest ratio (days to cover) is 18.3, indicating that it would take 18.3 days of the average trading volume of 2.15 million shares to cover all short positions. Ref: https://www.marketbeat.com/stocks/NASDAQ/PROK/short-interest/ Make your own DD because it's your money you're investing with! Here you are just a speck in a huge investment universe with billions in turnover! Strong forces
·21.7.So I sold at 5.68. And bought back in at 4.86… a bit stupid, but it's okay… And I think it's a good company to be in for the long term and I don't see the big problem in being the 30% in the red here. It's only lost when I sell.😬 From what I understand, the meeting has been there? Shortly after even. I think the hype about the increase. overshadowed the positive news at the meeting. They expect to have an update on the approval process in the first half of 2026. It just seems like a bit of a long time to wait. But I may have to then. The question for me is mostly whether this is an opportunity to buy more. Or take a loss, if you understand me here.- 9.7. · Muokattu9.7. · MuokattuTrekker frem et viktig utdrag fra oppdateringen. Ingen eksakt dato er kommunisert annet enn møte med FDA kommende uker: "We plan to submit the full results from REGEN-007 to ASN’s 2025 Kidney Week as a late-breaking clinical trial and are excited to share more details at that time with investors and the medical community,” said Bruce Culleton, M.D., CEO of ProKidney. “We also look forward to our upcoming FDA Type B meeting in the coming weeks to confirm our approach to eGFR slope as a surrogate endpoint for accelerated approval. This meeting represents an important step toward our goal of expediting rilparencel’s potential path to market in the U.S. where there remains a significant unmet clinical need in patients with advanced CKD and diabetes."·9.7. · MuokattuArter hours trading: 4.1100 +0.3800 +(10.19%) Investor presentation: https://www.sec.gov/Archives/edgar/data/1850270/000095017025094445/prok-ex99_2.htm
·8.7.Hopelessly slow to trade in the US, there is at least a 15 minute delay on all information.·9.7.Luckily I got most of it out yesterday. I saw a little later that there was one 0 too many in the order, so I skipped a bit :-)
·8.7.I feel like it's going to go up after this one opens again, but it's really scary to jump in. Does anyone have a publisher?
8.7.8.7.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
36 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9.7. · MuokattuThere is no answer before the stock market opens or the days go by. But from after/before trading, the big sums and green numbers are going since yesterday's close - at the time of writing over $5. Can the FDA meeting in the coming weeks be a trigger in itself and create fomo? I have read posts on the US forum when it was last at about $2.5, which mentioned 5X 10X at the time (no answer). Clearly, just a small market share can mean several 100 million a year in revenue. Regarding the short in the stock, it is large and explosive. The company has probably caught them on their heels: ProKidney (PROK) has a short interest of 16.80 million shares, representing 17.84% of the float (the number of shares available for trading by the public). This marks a 1.69% increase in short interest from the previous month. The short interest ratio (days to cover) is 18.3, indicating that it would take 18.3 days of the average trading volume of 2.15 million shares to cover all short positions. Ref: https://www.marketbeat.com/stocks/NASDAQ/PROK/short-interest/ Make your own DD because it's your money you're investing with! Here you are just a speck in a huge investment universe with billions in turnover! Strong forces·21.7.So I sold at 5.68. And bought back in at 4.86… a bit stupid, but it's okay… And I think it's a good company to be in for the long term and I don't see the big problem in being the 30% in the red here. It's only lost when I sell.😬 From what I understand, the meeting has been there? Shortly after even. I think the hype about the increase. overshadowed the positive news at the meeting. They expect to have an update on the approval process in the first half of 2026. It just seems like a bit of a long time to wait. But I may have to then. The question for me is mostly whether this is an opportunity to buy more. Or take a loss, if you understand me here.
- 9.7. · Muokattu9.7. · MuokattuTrekker frem et viktig utdrag fra oppdateringen. Ingen eksakt dato er kommunisert annet enn møte med FDA kommende uker: "We plan to submit the full results from REGEN-007 to ASN’s 2025 Kidney Week as a late-breaking clinical trial and are excited to share more details at that time with investors and the medical community,” said Bruce Culleton, M.D., CEO of ProKidney. “We also look forward to our upcoming FDA Type B meeting in the coming weeks to confirm our approach to eGFR slope as a surrogate endpoint for accelerated approval. This meeting represents an important step toward our goal of expediting rilparencel’s potential path to market in the U.S. where there remains a significant unmet clinical need in patients with advanced CKD and diabetes."·9.7. · MuokattuArter hours trading: 4.1100 +0.3800 +(10.19%) Investor presentation: https://www.sec.gov/Archives/edgar/data/1850270/000095017025094445/prok-ex99_2.htm
- ·8.7.Hopelessly slow to trade in the US, there is at least a 15 minute delay on all information.·9.7.Luckily I got most of it out yesterday. I saw a little later that there was one 0 too many in the order, so I skipped a bit :-)
- ·8.7.I feel like it's going to go up after this one opens again, but it's really scary to jump in. Does anyone have a publisher?8.7.8.7.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 518
Myynti
Määrä
1 020
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,19VWAP
Alin
2,1VaihtoMäärä
0,8 539 340
VWAP
Ylin
2,19Alin
2,1VaihtoMäärä
0,8 539 340
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 8.5.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 10.11. | |
| 2025 Q2 -tulosraportti | 12.8. | |
| 2025 Q1 -tulosraportti | 12.5. | |
| 2024 Q4 -tulosraportti | 17.3. | |
| 2024 Q3 -tulosraportti | 12.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
Vain PDF
36 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q1 -tulosraportti | 8.5.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 10.11. | |
| 2025 Q2 -tulosraportti | 12.8. | |
| 2025 Q1 -tulosraportti | 12.5. | |
| 2024 Q4 -tulosraportti | 17.3. | |
| 2024 Q3 -tulosraportti | 12.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9.7. · MuokattuThere is no answer before the stock market opens or the days go by. But from after/before trading, the big sums and green numbers are going since yesterday's close - at the time of writing over $5. Can the FDA meeting in the coming weeks be a trigger in itself and create fomo? I have read posts on the US forum when it was last at about $2.5, which mentioned 5X 10X at the time (no answer). Clearly, just a small market share can mean several 100 million a year in revenue. Regarding the short in the stock, it is large and explosive. The company has probably caught them on their heels: ProKidney (PROK) has a short interest of 16.80 million shares, representing 17.84% of the float (the number of shares available for trading by the public). This marks a 1.69% increase in short interest from the previous month. The short interest ratio (days to cover) is 18.3, indicating that it would take 18.3 days of the average trading volume of 2.15 million shares to cover all short positions. Ref: https://www.marketbeat.com/stocks/NASDAQ/PROK/short-interest/ Make your own DD because it's your money you're investing with! Here you are just a speck in a huge investment universe with billions in turnover! Strong forces·21.7.So I sold at 5.68. And bought back in at 4.86… a bit stupid, but it's okay… And I think it's a good company to be in for the long term and I don't see the big problem in being the 30% in the red here. It's only lost when I sell.😬 From what I understand, the meeting has been there? Shortly after even. I think the hype about the increase. overshadowed the positive news at the meeting. They expect to have an update on the approval process in the first half of 2026. It just seems like a bit of a long time to wait. But I may have to then. The question for me is mostly whether this is an opportunity to buy more. Or take a loss, if you understand me here.
- 9.7. · Muokattu9.7. · MuokattuTrekker frem et viktig utdrag fra oppdateringen. Ingen eksakt dato er kommunisert annet enn møte med FDA kommende uker: "We plan to submit the full results from REGEN-007 to ASN’s 2025 Kidney Week as a late-breaking clinical trial and are excited to share more details at that time with investors and the medical community,” said Bruce Culleton, M.D., CEO of ProKidney. “We also look forward to our upcoming FDA Type B meeting in the coming weeks to confirm our approach to eGFR slope as a surrogate endpoint for accelerated approval. This meeting represents an important step toward our goal of expediting rilparencel’s potential path to market in the U.S. where there remains a significant unmet clinical need in patients with advanced CKD and diabetes."·9.7. · MuokattuArter hours trading: 4.1100 +0.3800 +(10.19%) Investor presentation: https://www.sec.gov/Archives/edgar/data/1850270/000095017025094445/prok-ex99_2.htm
- ·8.7.Hopelessly slow to trade in the US, there is at least a 15 minute delay on all information.·9.7.Luckily I got most of it out yesterday. I saw a little later that there was one 0 too many in the order, so I skipped a bit :-)
- ·8.7.I feel like it's going to go up after this one opens again, but it's really scary to jump in. Does anyone have a publisher?8.7.8.7.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1 518
Myynti
Määrä
1 020
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,19VWAP
Alin
2,1VaihtoMäärä
0,8 539 340
VWAP
Ylin
2,19Alin
2,1VaihtoMäärä
0,8 539 340
Välittäjätilasto
Dataa ei löytynyt